Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …

Doxorubicin (DOX), a chemotherapeutic agent, induces a cardiotoxicity referred to as
doxorubicin-induced cardiomyopathy (DIC). This cardiotoxicity often limits chemotherapy for …

Necroptosis, which is distinct from apoptosis and necrosis, serves a crucial role in ontogeny
and the maintenance of homeostasis. In the last decade, it has been demonstrated that the …

Doxorubicin (DOX) is an effective anti-cancer agent for various malignancies. Nevertheless,
it has a side effect of cardiotoxicity, referred to as doxorubicin-induced cardiomyopathy …

The use of doxorubicin (DOX) to treat various tumors is limited by its cardiotoxicity. This
study aimed to investigate and compare the cardioprotective effects of nicotinamide (NAM) …

Anthracyclines are effective chemotherapeutic agents, commonly used in the treatment of a
variety of hematologic malignancies and solid tumors. However, their use is associated with …

Significance: The cardiac side effects of hematological treatments are a major issue of the
growing population of cancer survivors, often affecting patient survival even more than the …

Aims: Doxorubicin cardiomyopathy is a lethal pathology characterized by oxidative stress,
mitochondrial dysfunction, and contractile impairment, leading to cell death. Although …

Ca2+ signaling is implicated in the transition between microglial surveillance and activation.
Several L-type Ca2+ channel blockers (CCBs) have been shown to ameliorate …

Background Arrhythmias are one manifestation of the cardiotoxicity that results from
doxorubicin (Doxo) administration. Although cardiotoxicity is an anticipated outcome in …